AP NEWS

Adenosine A2A Receptor Antagonist - Pipeline Insight 2018 - ResearchAndMarkets.com

December 21, 2018

DUBLIN--(BUSINESS WIRE)--Dec 21, 2018--The “Adenosine A2A Receptor Antagonist -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Adenosine A2A Receptor Antagonist - Pipeline Insight, 2018′ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A2A Receptor Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Adenosine A2A Receptor Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Adenosine A2A Receptor Antagonist pipeline products by developmental stage, product type, molecule type, and administration route.

Key Topics Covered:

1. Report Introduction

2. Adenosine A2A Receptor Antagonist - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Adenosine A2A Receptor Antagonist Pipeline Products in Clinical Stages

6. Adenosine A2A Receptor Antagonist Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

Companies Mentioned

Vernalis Lewis and Clark Pharmaceuticals Heptares Therapeutics Advinus Therapeutics Roche Arcus Biosciences iTeos Therapeutics Faust Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/c7q62r/adenosine_a2a?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181221005385/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/21/2018 11:43 AM/DISC: 12/21/2018 11:43 AM

http://www.businesswire.com/news/home/20181221005385/en

AP RADIO
Update hourly